H-type essential hypertension
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Blood pressure >= 130/80 mmHg and/or has been diagnosed with high blood pressure, and normal blood pressure after treatment (the treatment plan is Valsartan capsule 80mg qd), and Hcy >= 10µmol/L; 2. Comply with phlegm and blood stasis syndrome, and liver stagnation syndrome-those with the following 3 main syndromes or 2 main syndromes plus 2 or more secondary syndromes can be diagnosed: Main symptoms: (1) limbs are heavy and full of abdominal distension; (2) Tingling, pain has a fixed place; (3) Emotional depression or irritability, irritability, goodness and rest; Secondary evidence: (1)flank pain; (2) nausea and vomiting; (3) veins and ecchymosis (lips, gums, dark purple nails, red skin on the muscle surface);(4) The tongue is greasy or the tongue is dark purple or has ecchymosis, petechiae, and thick tongue veins; (5) pulse string or pulse string; (6) local sensory disturbance. 3. The age is 30~75 years old; 4. Those who agree to cooperate with the collection of data and improve relevant inspections; 5. Those who voluntarily signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Complicated with severe cardiovascular and cerebrovascular diseases (such as cardiac insufficiency, acute myocardial infarction, cerebral infarction, cerebral hemorrhage, etc.), liver and kidney dysfunction, mental disorders and other diseases; 2. Those who are unwilling to cooperate with data collection and blood drawing; 3. Women during pregnancy or lactation; 4. Patients who have used other antihypertensive drugs other than valsartan capsules or have high blood lipid levels and need to use lipid-lowering drugs; 5. Other circumstances that the researcher thinks are not suitable for participating in this research.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood pressure;Homocysteine; | — |
Countries
China
Contacts
Guangzhou University of Chinese Medicine